Teratogenic action of platinum thymine blue.
The teratogenic activity of the antitumor agent cisplatinum-2-thymine (platinum thymine blue) was investigated in rats. Pregnant Wistar-derived albino rats were given single ip injections of an aqueous solution of platinum thymine blue (PTB) at one day of pregnancy from day 5 through day 14 (sperm day=day 0). The dosages used ranged from 20 to 80 mg/kg maternal body weight. At autopsy (day 20) fetuses were recovered and subsequently examined for skeletal and soft-tissue abnormalities. PTB was embryolethal and teratogenic at several stages during rat gestation. Embryonic death occurred following all doses, and was dose dependent, except at day 5. The majority of malformed fetuses, however, were observed only after treatment at day 6 or 7 following injection with 50, 60, or 80 mg/kg. Eye defects were the predominant abnormality followed by hydrocephalus, gastroschisis, and ectopia cordis. The skeleton was only slightly affected. PTB is a potent inhibitor of DNA synthesis, but its mechanism of teratogenic action is unknown.
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001842:Bone and Bones / Q000002:abnormalities; D001921:Brain / Q000002:abnormalities; D004247:DNA / Q000096:biosynthesis; D005260:Female; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000378:metabolism; D011247:Pregnancy; D051381:Rats
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; C023360:platinum thymine blue; D004247:DNA